Loading…
Specialty biopharma selling narcolepsy drugs (Xywav, Xyrem), epilepsy drug Epidiolex, and oncology treatments.
Specialty biopharma selling narcolepsy drugs (Xywav, Xyrem), epilepsy drug Epidiolex, and oncology treatments.
Sells its sleep drugs through a single central pharmacy under a safety program required for the active ingredient, sodium oxybate. Buying GW Pharmaceuticals in 2021 added Epidiolex, and Zepzelca is licensed from PharmaMar. The company is based in Ireland.
Moat: narrow (IP / patents, regulatory licence). Controlled-substance distribution expertise and patents on its oxybate franchise limit direct generic competition.
Headquarters: Dublin, Ireland · Founded: 2003 · Employees: 2,890
Size Jazz Pharmaceuticals Public (JAZZ) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $15.1B, the 597th largest of 3,117 United States companies the cockpit tracks. Shares closed at $234.76 on 6 Nov 2026.
Performance Over six months the shares gained 4.0%, against +6.3% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 13.5% over the last twelve months (peer median +18.9%); the operating margin is 24.8% (peer median 20.4%).
Valuation It trades at 8.9× forward earnings against a peer median of 29.8× (cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.8 points above its cost of capital (6.4% WACC).
Credit Jazz Pharmaceuticals Public has 2 bonds outstanding ($2.50B), rated BB+ by the agencies and trading like BBB- at a weighted spread of 110 bp.
Short interest Short interest is 9.0% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.72B | $4.27B | $4.07B | $3.83B | $3.66B |
| Revenue growth | — | +5% | +6% | +5% | — |
| Gross profit | $3.52B | $3.11B | $3.00B | $2.79B | $2.52B |
| EBITDA | $1.89B | $1.45B | $1.39B | $1.30B | $1.35B |
| Net income | $206M | -$356M | $560M | $415M | -$224M |
| Free cash flow | $1.62B | $1.30B | $1.36B | $1.07B | $1.24B |
| Capital expenditure | $201M | $167M | $38.1M | $24.0M | $54.0M |
| Total debt | $5.64B | $5.43B | $6.17B | $5.80B | $5.82B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% |
| Harmony Biosciences HRMY | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% |
| Alkermes Public ALKS | $7.71B | +31% | +15% | 5% | n/a | 31.5% |
| Axsome Therapeutics AXSM | $6.96B | -39% | +54% | -19% | 75.5× | n/a |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% |
| SKBP 326030.KS | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JAZZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.5% | +8.1% | 8th lowest of 21 |
| 6-month return | +4.0% | +6.3% | 10th lowest of 21 |
| Distance from 52-week high | -11.9% | -9.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +13.5% | +18.9% | 6th lowest of 21 |
| Operating margin | 24.8% | 20.4% | 9th highest of 21 |
| Forward P/E | 8.9× | 29.8× | cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -3.9% | 11.7% | 4th least demanding of 18 |
| Growth delivered (Del g) | +12.5% | +12.1% | 9th highest of 18 |
| Hurdle (Req g minus delivered) | -16.5 pp | -10.8 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | +6.8 pp | +1.8 pp | 10th highest of 21 |
| EV / EBITDA | 9.5× | 17.1× | 3rd cheapest of 15 |
| Net debt / EBITDA | 1.5× | -0.1× | 3rd most indebted of 16 |
| Bond spread | 110 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.8B | +118% | +64% | 38% | 39.2× | 29.3% | +94.8% |
| Ascendis Pharma A/S ASND | United States | $16.0B | +8% | +128% | 10% | 40.8× | 36.4% | +152.4% |
| Orion ORNAV.HE | Finland | $16.1B | +51% | +34% | 38% | 23.5× | -6.3% | +11.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 25.5× | -1.1% | +13.1% |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% | +11.3% |
| Innovent Biologics 1801.HK | Hong Kong | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% | +26.8% |
| Pharmaron Beijing 3759.HK | Hong Kong | $11.3B | +45% | +24% | 14% | 22.9× | n/a | n/a |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
Jazz Pharmaceuticals Public has 2 bonds outstanding with $2.50B face value. The agencies rate it BB+; its bonds trade like BBB-. Weighted yield 5.63%, a spread of 110 bp over government bonds.